Relapsed or Refractory Multiple Myeloma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Relapsed or Refractory Multiple Myeloma Market Outlook

Thelansis’s “Relapsed or Refractory Multiple Myeloma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Multiple Myeloma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Relapsed or Refractory Multiple Myeloma Overview

Multiple myeloma (MM) is a challenging hematological malignancy characterized by the uncontrollable growth of clonal plasma cells in the bone marrow. These cells produce significant quantities of immunoglobulins and other non-functional proteins. Despite numerous decades of progress and groundbreaking therapeutic advancements, MM remains largely incurable. These highly proliferative, differentiated B-lymphocytes can secrete a range of immunoglobulins (Ig), with IgG and IgA being the most common and IgD to a lesser extent. Typically, the abnormal plasma cells primarily reside in the bone marrow, and only a small minority of patients exhibit extramedullary disease at diagnosis. Most patients experience relapses during treatment, progressing to a refractory state, where they no longer respond to treatment within approximately 60 days after their last therapy. A bleak prognosis and a heightened risk of relapse characterize this. With each successive relapse, the progression-free survival (PFS) period tends to become progressively shorter. PFS spans 18 months for first-line patients, but by the fourth line of therapy, it dwindles to just 4.7 months. The principal objective of treating relapsed MM is to alleviate disease symptoms and prevent the emergence of CRAB symptoms, denoted by elevated calcium levels (>11.5 mg/dL), high creatinine levels (>2 mg/dL), low hemoglobin levels (<10 g/dL or >2 points below the lower normal limit), and the development of new bone lesions. Managing relapsed and refractory multiple myeloma (RRMM) entails a multifaceted approach that combines proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, often supplemented with histone deacetylase inhibitors and alkylating agents.

• In the USA, the incidence of Multiple myeloma ranges from 5 to 9 cases per 100,000 population per year with 45% of 5-year survival.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: